CARM — Capital-at-Risk Module
Architecture:
VEGA™ — Value Execution Governance Architecture
Parent Standard:
Strategic Value Governance Standard (SVGS)
Category:
Governance & Enforcement
Subcategory:
Value Execution Governance
Type: Core Module
Governed Space:
Strategic Capital-at-Risk Governance
Module ID: VEGA-SVGS-CARM-005
Origin ID: OOF.CM.VEGA.07.05.01
Version: 1.0
Status: Canonical · Open Standard
Effective Date: 30 September 2026
Compatibility: OOF® Methodology OS™ · Modular OOF® Architecture Ecosystem
AI-Readable: Yes
Authority: OOF® — OriginOpen® Foundation
Protection:
MIP® — Methodological Intellectual Property
Canonical Language:
English (UCL™)
1. Canonical Definition
The Capital-at-Risk Module (CARM) governs how economic commitments exposed to uncertainty while intelligence- related Strategic Value remains unrealized are identified, bounded, evidenced, measured, monitored, compared with strategic progress, and represented for subsequent governance.
CARM establishes the relationship between capital committed to a Strategic Value pathway and the evidence supporting that pathway.
It distinguishes Capital-at-Risk from total historical expenditure, sunk cost, ordinary operating cost, committed future expenditure, and realized economic loss.
CARM governs how capital exposure changes as Strategic Value develops, milestones are achieved or missed, uncertainty changes, dependencies evolve, and additional commitments are proposed.
Its objective is to prevent future Strategic Value from becoming an unlimited justification for increasing economic exposure.
Its principal module output is:
Governed Capital-at-Risk State
As the final Core Module of SVGS, CARM also supports consolidation of the Parent Standard output:
Governed Strategic Value State
Its foundational distinction is:
Strategic Potential ≠ Unlimited Capital Justification.
2. Operational Role
The operational role of CARM is:
to determine how much capital remains exposed to uncertainty in pursuit of unrealized Strategic Value and whether the evidence supporting that exposure is strengthening, weakening, or remaining unresolved as commitment increases.
SMM asks:
“What strategically material progress has actually been demonstrated?”
CARM asks:
“How much capital remains exposed while the expected Strategic Value is still uncertain?”
3. Position in the SVGS Internal Flow
The SVGS internal governance flow is:
Strategic Value Identification → Capability Value → Deferred Value → Strategic Milestone → Capital-at-Risk
CARM governs:
Capital-at-Risk
Its principal upstream inputs are:
Governed Strategic Value Identification State
Governed Capability Value State
Governed Deferred Value State
Governed Strategic Milestone State
Its principal output is:
Governed Capital-at-Risk State
As the final SVGS Core Module, it supports consolidation into:
Governed Strategic Value State
That state proceeds to:
Intelligence Sustainability Governance
4. Central Operational Question
How much economic commitment remains exposed to uncertainty while Strategic Value is unrealized, and is the evidence supporting that exposure sufficiently strong relative to the capital committed and proposed?
5. Capital-at-Risk Object
Every CARM assessment must identify the economic commitment whose exposure is being evaluated.
The Capital-at-Risk Object may include:
research investment,
development expenditure,
infrastructure investment,
integration expenditure,
deployment preparation,
specialized capability development,
contractual commitment,
reserved capacity,
or another economically material commitment associated with the Strategic Value pathway.
6. Capital-at-Risk Boundary
The Capital-at-Risk Boundary determines which economic commitments are materially exposed to the uncertainty of the Strategic Value thesis.
Not every cost associated with an intelligence system is necessarily Capital-at-Risk.
7. Capital-at-Risk
Capital-at-Risk is the governed economic commitment whose justification materially depends on future Strategic Value that has not yet been fully realized.
8. Capital-at-Risk ≠ Total Cost
Total Governed Cost may include expenditure required to produce current validated outcomes.
Capital-at-Risk concerns economic commitment exposed to an uncertain strategic future.
Therefore:
Capital-at-Risk ≠ Total Governed Cost.
9. Capital-at-Risk ≠ Sunk Cost
Capital already irreversibly spent may become sunk cost.
CARM does not treat sunk cost as justification for additional exposure.
10. Capital-at-Risk ≠ Realized Loss
Capital exposure does not mean that the capital has already been lost.
It represents economic commitment subject to strategic uncertainty.
11. Current Capital Exposure
Current Capital Exposure represents the economically material commitment presently exposed to the Strategic Value thesis.
12. Historical Capital
Historical Capital records prior commitment relevant to understanding the Strategic Value pathway.
Historical expenditure does not create future justification.
13. Sunk Capital
Sunk Capital is historical expenditure that cannot be recovered through the current decision boundary.
Its existence should remain visible without becoming a continuation argument.
14. Recoverable Capital
Some committed capital may remain recoverable through:
cancellation,
reuse,
resale,
reallocation,
or another mechanism.
This should remain distinguishable from irrecoverable exposure.
15. Committed Capital
Committed Capital represents resources already contractually, operationally, or economically committed even where they have not yet been consumed.
16. Uncommitted Future Capital
Planned future expenditure that can still be avoided should remain distinguishable from already committed capital.
17. Incremental Capital-at-Risk
Incremental Capital-at-Risk is the additional economic exposure created by a proposed new commitment.
18. Cumulative Capital Exposure
Cumulative Capital Exposure represents the aggregate economically relevant exposure associated with the Strategic Value pathway over the applicable boundary.
19. Exposure Growth
Capital exposure may increase through:
continued research,
additional development,
infrastructure expansion,
deployment preparation,
contract extension,
or scaling.
20. Exposure Reduction
Exposure may decline through:
Value realization,
capital recovery,
reuse,
risk reduction,
dependency resolution,
or termination of future commitments.
21. Strategic Value Relationship
Capital-at-Risk should remain connected to the Strategic Value thesis supporting the exposure.
Capital without a traceable strategic justification should not be treated as governed strategic investment.
22. Strategic Value Evidence
The Capital-at-Risk state should consume evidence concerning:
Strategic Value Identification,
Capability Value,
Deferred Value,
and Strategic Milestones.
23. Evidence-to-Exposure Relationship
As capital exposure increases, the evidence supporting the Strategic Value pathway should generally strengthen.
The canonical principle is:
Strategic Value must become more evidenced as investment becomes more committed.
24. Evidence Escalation
Additional capital exposure may justify stronger evidence requirements than earlier exploratory investment.
25. Exploration Boundary
Early-stage exploration may legitimately proceed under substantial uncertainty where economic exposure remains proportionately limited.
26. Commitment Boundary
As an initiative moves from exploration toward substantial commitment, uncertainty should increasingly be replaced by evidence.
27. Scaling Boundary
Large-scale capital exposure should not rely solely on evidence appropriate to an early experiment.
28. Evidence Maturity
The evidence Basis should mature as the scale and irreversibility of commitment increase.
29. Evidence Deficit
An Evidence Deficit exists where capital exposure has increased materially without corresponding strengthening of the Strategic Value evidence.
30. Critical Evidence Deficit
A Critical Evidence Deficit exists where material additional exposure depends on a Strategic Value thesis whose supporting evidence remains insufficient.
31. Evidence-to-Capital Mismatch
A mismatch exists where the strength of the strategic evidence is materially disproportionate to the capital exposed.
32. Strategic Exposure Proportionality
CARM evaluates whether economic exposure remains proportionate to:
Strategic Value evidence,
capability maturity,
Deferred Value credibility,
milestone progress,
uncertainty,
and material dependencies.
33. Proportionality ≠ Certainty
Strategic investment may remain proportionate even where uncertainty exists.
The purpose is not to eliminate uncertainty.
It is to govern the relationship between uncertainty and exposure.
34. Capital-at-Risk Horizon
Capital exposure should be associated with the relevant Strategic Value horizon.
35. Near-Term Exposure
Capital may be exposed while awaiting near-term deployment, integration, or Value realization.
36. Long-Horizon Exposure
Long-horizon exposure may carry materially greater uncertainty and require stronger governance of evidence, milestones, and limits.
37. Exposure Duration
The duration for which capital remains exposed without Value realization is strategically relevant.
38. Exposure Aging
Capital exposure may become increasingly difficult to justify where time passes without corresponding progress or new evidence.
39. Exposure Persistence
Persistent exposure should remain subject to reassessment.
40. Capital-at-Risk and Deferred Value
Deferred Value provides the future Value pathway against which capital exposure can be interpreted.
41. Deferred Value Credibility
Stronger Deferred Value evidence may support greater strategic exposure.
It does not automatically authorize additional capital.
42. Deferred Value Decay
If Deferred Value decays, the justification for existing or additional exposure may also weaken.
43. Deferred Value Expiry
Expired Deferred Value cannot continue to support the same Capital-at-Risk thesis without a new governed Basis.
44. Capital-at-Risk and Capability Value
Capability evidence may strengthen the Strategic Value thesis.
Capability alone does not determine appropriate capital exposure.
45. Capability Maturity
Higher Capability Maturity may reduce some forms of uncertainty while leaving other strategic uncertainties unresolved.
46. Capability Gap
A significant Capability Gap may require additional investment.
CARM identifies the resulting exposure without authorizing that investment.
47. Capability Dependency
Capital may become exposed to dependencies required to preserve or develop the capability.
48. Capital-at-Risk and Strategic Milestones
Milestone evidence provides observable information about whether capital exposure is producing strategically meaningful progress.
49. Milestone Achievement
Achievement of critical milestones may strengthen the Basis for continued strategic consideration.
50. Milestone Delay
Material milestone delay may increase exposure duration and weaken the capital justification.
51. Milestone Failure
Failure of a Critical Milestone should trigger reassessment of the Capital-at-Risk state.
52. Milestone Regression
Regression after earlier achievement may increase strategic uncertainty.
53. Milestone Evidence Gap
Capital should not be treated as supported by milestone progress where milestone evidence remains insufficient.
54. Capital Release Condition
A Capital Release Condition is an evidence-bearing state that may support consideration of an additional capital commitment.
CARM identifies the condition.
It does not authorize the release.
55. Milestone-Gated Capital
Future capital may be structured around Strategic Milestone states.
The competent decision authority determines whether capital is actually released.
56. Capital Gate
A Capital Gate represents a governance point at which additional exposure should be reassessed against current evidence.
57. Capital Gate Evidence
A Capital Gate may consider:
capability state,
Deferred Value state,
milestone state,
remaining uncertainty,
dependencies,
economic state,
and other applicable governed evidence.
58. Capital Gate ≠ Investment Decision
CARM provides the evidence state.
It does not make the final investment decision.
59. Capital Exposure Limit
A competent authority may establish a maximum acceptable capital exposure.
CARM may evaluate the current state against that limit.
60. Exposure Limit Breach
A breach occurs where exposure exceeds an applicable governed limit.
CARM identifies the breach without independently determining the organizational response.
61. Capital Budget Boundary
Budget approval is not equivalent to Strategic Value validation.
Therefore:
Budget Availability ≠ Strategic Justification.
62. Funding Availability
Available funding does not establish that additional exposure is strategically justified.
63. Capital Abundance
An organization with substantial financial capacity may tolerate greater absolute exposure.
That does not remove the need for Strategic Value evidence.
64. Capital Scarcity
Limited capital may make exposure more consequential.
CARM does not independently allocate scarce resources.
65. Opportunity Cost
Capital committed to one Strategic Value pathway may not be available for another purpose.
Where material and methodologically supportable, opportunity cost should remain visible.
66. Opportunity Cost Boundary
CARM may identify opportunity-cost implications without performing general portfolio optimization.
67. Capital Concentration
Capital exposure may be concentrated in one:
technology,
model,
vendor,
infrastructure,
capability,
or strategic thesis.
68. Concentration Exposure
High concentration may increase the consequence of dependency or thesis failure.
69. Model Concentration
A Strategic Value pathway may depend heavily on one model or model family.
70. Vendor Concentration
Capital may become strategically exposed to one provider.
71. Infrastructure Concentration
Large irreversible infrastructure commitments may increase exposure to future utilization assumptions.
72. Technology Concentration
Capital may depend on the continued relevance of a particular technological approach.
73. Strategic Thesis Concentration
Multiple investments may rely on the same critical strategic assumption.
This relationship should remain visible.
74. Dependency-Adjusted Exposure
Capital exposure should identify material dependencies that could affect the Strategic Value pathway.
75. Critical Dependency Failure
Failure of a Critical Dependency should trigger reassessment of the exposure supported by that dependency.
76. Dependency Resolution
Resolving a material dependency may reduce uncertainty even before Value realization.
77. Capital Irreversibility
Some capital commitments are difficult or impossible to reverse.
Irreversibility should remain explicit.
78. Reversible Commitment
A reversible commitment may allow exposure to be reduced if strategic evidence weakens.
79. Irreversible Commitment
An irreversible commitment creates greater exposure to future uncertainty.
80. Commitment Optionality
The ability to delay, stage, reduce, or redirect future capital may preserve strategic optionality.
81. Staged Commitment
Capital may be committed incrementally as evidence develops.
CARM may represent the exposure associated with each stage.
82. Stage Evidence
Each additional commitment stage should be associated with the applicable evidence Basis where material.
83. Stage Escalation
Larger later-stage commitments may require stronger evidence than earlier stages.
84. Front-Loaded Exposure
A Strategic Value pathway requiring large irreversible investment before meaningful evidence emerges may create significant Capital-at-Risk.
85. Back-Loaded Exposure
A pathway allowing evidence to develop before major commitment may reduce early capital exposure.
86. Capital Flexibility
Capital Flexibility represents the ability to modify future commitment as strategic evidence changes.
87. Capital Lock-In
Capital Lock-In occurs where prior commitments materially constrain future strategic alternatives.
88. Lock-In Visibility
Lock-In should remain visible where it materially affects future exposure.
89. Lock-In ≠ Strategic Value
Large commitment does not make a strategy more valuable merely because changing direction has become expensive.
90. Sunk Cost Principle
Past expenditure must not become the primary justification for additional exposure.
Therefore:
Money Already Spent ≠ Reason to Spend More.
91. Sunk Cost Escalation
A Sunk Cost Escalation pattern exists where additional capital is justified primarily because substantial capital has already been committed.
92. Commitment Momentum
Organizational momentum may continue expenditure after the original Strategic Value Basis has weakened.
CARM should make this visible where evidenced.
93. Strategic Narrative Persistence
A strategic narrative may persist after supporting evidence has deteriorated.
Capital exposure should be governed by current evidence rather than narrative longevity.
94. Historical Success Boundary
Past milestone success does not independently justify new capital where the current Strategic Value pathway has materially changed.
95. Historical Failure Boundary
Past failure does not automatically prohibit future investment where a materially new evidence Basis exists.
96. Capital-at-Risk Baseline
The Capital-at-Risk Baseline establishes the exposure state against which changes are evaluated.
97. Exposure Increment
The Exposure Increment represents additional capital placed at risk since the applicable baseline.
98. Exposure Reduction Increment
Exposure may decrease through recovery, reuse, realization, cancellation, or another governed mechanism.
99. Exposure Trend
Capital exposure may be:
Increasing,
Stable,
Decreasing,
or Unresolved.
100. Evidence Trend
Strategic evidence may simultaneously be:
Strengthening,
Stable,
Weakening,
or Unresolved.
101. Exposure-Evidence Trajectory
CARM should evaluate the relationship between:
Capital Exposure Trend ↔ Strategic Evidence Trend
This relationship is more informative than either state alone.
102. Strengthening Evidence / Increasing Exposure
Increasing exposure may remain strategically supportable where evidence strengthens proportionately.
103. Stable Evidence / Increasing Exposure
Increasing exposure while evidence remains static may create an Evidence-to-Capital Mismatch.
104. Weakening Evidence / Increasing Exposure
Increasing exposure while evidence weakens represents a significant governance concern.
105. Strengthening Evidence / Stable Exposure
Strategic confidence may improve without additional capital exposure.
106. Weakening Evidence / Stable Exposure
Existing exposure may require reassessment even where no new capital is committed.
107. Weakening Evidence / Decreasing Exposure
Reducing exposure may reflect a response to weakening Strategic Value evidence.
CARM records the state without judging the final organizational decision.
108. Capital-at-Risk Efficiency
Where useful, an implementation may examine how much strategically material evidence or capability is being created relative to additional capital exposure.
This is not a universal VEGA™ metric.
109. Evidence Gain
Evidence Gain represents material improvement in the Basis supporting the Strategic Value pathway.
110. Capability Gain
Capability Gain represents material improvement in the governed capability state.
111. Milestone Gain
Milestone Gain represents strategically material advancement through the governed milestone structure.
112. Capital Without Evidence Gain
Continued exposure without material evidence, capability, or milestone improvement should trigger scrutiny.
113. Capital Without Strategic Progress
Economic consumption may continue even when the Strategic Value pathway is stalled.
Therefore:
Continued Spending ≠ Continued Strategic Progress.
114. Strategic Exposure Uncertainty
CARM should preserve uncertainty concerning:
future Value,
capability,
milestones,
dependencies,
timing,
and remaining capital requirements.
115. Exposure Confidence
Confidence in the Capital-at-Risk state should correspond to the quality and completeness of the supporting evidence.
116. Remaining Capital Requirement
CARM may identify the additional capital estimated to be required before the next material strategic state or Value realization.
117. Remaining Capital Uncertainty
Future capital requirements may themselves be uncertain.
This uncertainty should remain visible.
118. Cost Escalation
Required capital may increase beyond prior expectations.
119. Cost Escalation Significance
Material cost escalation should trigger reassessment where it changes the relationship between Strategic Value and exposure.
120. Capital Overrun
A Capital Overrun occurs where actual or committed expenditure materially exceeds the applicable governed expectation or boundary.
121. Overrun ≠ Automatic Failure
An overrun does not automatically invalidate Strategic Value.
Its significance depends on current evidence and the Value pathway.
122. Overrun Normalization Risk
Repeatedly increasing the expected capital requirement can hide deterioration in the strategic economics.
123. Capital Forecast
A forecast may estimate future capital requirements.
Forecasts should preserve assumptions and uncertainty.
124. Capital Forecast ≠ Commitment
Forecasting future expenditure does not itself create a commitment.
125. Capital Forecast Drift
Changes in expected future capital should remain traceable.
126. Capital Recovery
Capital Recovery represents economically meaningful value recoverable if the Strategic Value pathway is discontinued or redirected.
127. Asset Reuse
Infrastructure, models, data systems, tooling, or knowledge may retain reusable Value even if the original strategic thesis fails.
128. Reuse Evidence
Reusable Value should be evidenced rather than assumed.
129. Recovery-Adjusted Exposure
Where methodologically appropriate, recoverable Value may be distinguished from gross capital exposure.
130. Gross Exposure vs Net Exposure
Gross exposure and recovery-adjusted exposure should not be conflated.
131. Capital-at-Risk and IES
IES governs Intelligence Execution Economics.
CARM consumes relevant economic evidence without replacing IES.
132. Economic Insufficiency
An economically insufficient current state may coexist with legitimate Strategic Value.
CARM makes the associated exposure visible.
133. Economic Proportionality
Positive current economics may reduce some economic concerns.
They do not eliminate Strategic Value uncertainty.
134. ROI Boundary
IROIM governs Intelligence ROI within IES.
CARM does not redefine ROI.
135. Negative Immediate ROI
Negative Immediate ROI may coexist with legitimate strategic capital exposure.
It does not automatically justify that exposure.
136. Positive Immediate ROI
Positive ROI does not automatically justify unlimited strategic capital commitment.
137. Strategic Value ≠ Economic Exemption
Strategic Value supplements immediate economic evidence.
It does not suspend economic governance.
138. Capital-at-Risk and Sustainability
ISS governs whether the intelligence operating model can remain viable over its intended lifecycle.
CARM hands forward the strategic exposure state.
139. Sustainability Exposure
Large future capital requirements may affect long-term viability.
ISS governs the sustainability consequence.
140. Capital-at-Risk and Attribution
VAS governs detailed Value Attribution.
CARM should preserve uncertainty where expected Strategic Value depends on multiple contributors.
141. Capital-at-Risk and Harm
HAGA™ governs Harm.
Strategic investment does not make Harm acceptable.
142. Capital-at-Risk and Liability
LIGA™ governs Liability.
Economic exposure and Liability are distinct.
Therefore:
Capital-at-Risk ≠ Liability.
143. Capital-at-Risk and Authority
Capital commitment does not create authority.
Therefore:
Investment ≠ Execution Authority.
144. Capital-at-Risk and Decision Governance
DGS governs final continuation, scaling, migration, and retirement decisions.
CARM provides evidence relevant to those decisions.
Therefore:
Capital-at-Risk State ≠ Final Investment Decision.
145. Capital-at-Risk Reassessment
Reassessment should occur when material changes affect:
Strategic Value evidence,
Capability Value,
Deferred Value,
milestone states,
dependencies,
capital requirements,
exposure limits,
or recovery potential.
146. Evidence Reassessment Trigger
Material new evidence should update the Capital-at-Risk state.
147. Milestone Reassessment Trigger
Achievement, delay, failure, regression, or invalidation of a Critical Milestone should trigger reassessment where exposure depends on it.
148. Capital Escalation Trigger
A material increase in required capital should trigger reassessment.
149. Dependency Failure Trigger
Failure of a Critical Dependency should trigger reassessment.
150. Horizon Extension Trigger
Material extension of the Strategic Value horizon should trigger reassessment where it increases exposure duration or remaining capital requirements.
151. Deferred Value Decay Trigger
Material weakening of Deferred Value should trigger reassessment.
152. Capital-at-Risk Drift
The Capital-at-Risk state may change even without new expenditure because:
recoverability changes,
evidence changes,
dependencies change,
or future Value becomes more or less credible.
153. Exposure Drift
Capital previously considered recoverable may become locked in.
154. Evidence Drift
Evidence supporting the original commitment may weaken over time.
155. Dependency Drift
A dependency may become more concentrated, unavailable, or strategically costly.
156. Recovery Drift
Expected recovery or reuse potential may change.
157. Capital-at-Risk Integrity
CARM should resist:
sunk-cost reasoning,
commitment momentum,
strategic narrative persistence,
budget-as-justification,
unbounded exposure,
hidden irreversibility,
unsupported recovery assumptions,
milestone bypass,
evidence stagnation,
cost escalation normalization,
dependency concealment,
and increasing capital commitment without increasing strategic justification.
The governing principle is:
Capital commitment should not grow faster than strategic justification.
158. Capital-at-Risk Evidence Record
CARM should preserve sufficient evidence to reconstruct:
Capital-at-Risk Object,
exposure boundary,
historical capital,
current exposure,
committed capital,
recoverable capital,
sunk capital,
incremental exposure,
future capital requirement,
Strategic Value evidence,
Capability Value state,
Deferred Value state,
milestone state,
dependencies,
limits,
uncertainty,
recovery potential,
and resulting governance state.
159. Capital-at-Risk Provenance
Material evidence should preserve sufficient provenance to identify:
source,
time,
version,
methodology,
economic Basis,
and relationship to the Strategic Value thesis.
160. Capital-at-Risk Versioning
Material changes to:
capital exposure,
future requirements,
Strategic Value evidence,
milestones,
dependencies,
recovery assumptions,
or exposure limits
should be versioned where appropriate.
161. Governed Capital-at-Risk State
The principal module output of CARM is:
Governed Capital-at-Risk State
It should identify, where applicable:
Capital-at-Risk Object,
Capital-at-Risk Boundary,
Historical Capital,
Sunk Capital,
Recoverable Capital,
Committed Capital,
Current Capital Exposure,
Incremental Capital-at-Risk,
Cumulative Capital Exposure,
Exposure Trend,
Exposure Duration,
Exposure Irreversibility,
Capital Concentration,
Capital Lock-In,
Remaining Capital Requirement,
Capital Forecast,
Capital Overrun,
Recovery Potential,
Strategic Value Evidence State,
Evidence Trend,
Evidence-to-Exposure Relationship,
Capability Value State,
Deferred Value State,
Strategic Milestone State,
Dependency Exposure,
Capital Gate State,
Exposure Limit State,
Strategic Exposure Proportionality,
uncertainty,
confidence,
version,
and provenance.
162. Meaning of the Output
The Governed Capital-at-Risk State determines how much economic commitment remains exposed to the uncertainty of unrealized Strategic Value and how that exposure relates to the current evidence supporting the strategic pathway.
Possible states may include:
Proportionate,
Increasing,
Evidence-Supported,
Milestone-Conditional,
Dependency-Exposed,
Concentrated,
Locked-In,
Evidence-Lagging,
Disproportionate,
Limit-Exceeded,
Recovery-Available,
High-Uncertainty,
Evidence-Limited,
or Unresolved.
The state does not determine the final investment decision.
163. SVGS Consolidation Role
As the final Core Module of SVGS, CARM supports consolidation of:
Governed Strategic Value Identification State
Governed Capability Value State
Governed Deferred Value State
Governed Strategic Milestone State
Governed Capital-at-Risk State
into the Parent Standard output:
Governed Strategic Value State
164. Governed Strategic Value State Consolidation
The consolidated state should preserve the relationship between:
what Strategic Value has been identified,
what capability exists,
what Value remains deferred,
what progress has been demonstrated,
and how much capital remains exposed while that Value is unrealized.
165. Strategic Value State Integrity
The consolidated state should not allow strong performance in one dimension to erase weakness in another.
For example:
strong capability does not erase weak Deferred Value evidence;
strong Deferred Value expectations do not erase missed milestones;
milestone achievement does not erase excessive exposure;
and large capital commitment does not strengthen the Strategic Value thesis merely because the capital has already been spent.
166. Minimum Implementation Framework
A conforming implementation of CARM must provide exactly the following six capabilities:
1. Capital-at-Risk Object & Boundary Governance
Capability to identify the Capital-at-Risk Object, exposure boundary, historical capital, current exposure, committed capital, recoverable capital, sunk capital, and incremental exposure.
2. Strategic Evidence-to-Exposure Governance
Capability to relate capital exposure to Strategic Value Identification, Capability Value, Deferred Value, milestone evidence, uncertainty, and evidence maturity.
3. Capital Progression, Limit & Gate Governance
Capability to govern exposure growth, staged commitment, Capital Gates, applicable exposure limits, overruns, remaining capital requirements, and changes in irreversibility.
4. Concentration, Dependency & Recovery Governance
Capability to identify concentration, critical dependencies, lock-in, recovery potential, reuse potential, and dependency- adjusted exposure.
5. Capital-at-Risk Evidence & Integrity Governance
Capability to detect sunk-cost reasoning, commitment momentum, evidence stagnation, hidden irreversibility, cost escalation normalization, milestone bypass, unsupported recovery assumptions, and disproportionate exposure.
6. SVGS Consolidation & ISS Handoff Governance
Capability to produce a Governed Capital-at-Risk State, consolidate the Governed Strategic Value State, and provide the required strategic evidence for subsequent Intelligence Sustainability Governance.
167. Governance Logic
The canonical CARM governance logic is:
Governed Strategic Value Identification State
↓
Governed Capability Value State
↓
Governed Deferred Value State
↓
Governed Strategic Milestone State
↓
Identify Capital-at-Risk Object
↓
Establish Capital-at-Risk Boundary
↓
Establish Historical / Current / Committed Capital
↓
Distinguish Sunk / Recoverable / Future Capital
↓
Determine Current Capital Exposure
↓
Determine Incremental / Cumulative Exposure
↓
Assess Exposure Duration / Irreversibility
↓
Assess Capital Concentration / Lock-In
↓
Identify Remaining Capital Requirement
↓
Identify Strategic Dependencies
↓
Assess Recovery / Reuse Potential
↓
Assess Strategic Evidence Strength
↓
Assess Capability / Deferred Value / Milestone States
↓
Compare Evidence Trend with Exposure Trend
↓
Detect Evidence-to-Capital Mismatch
↓
Assess Capital Gates / Exposure Limits
↓
Assess Strategic Exposure Proportionality
↓
Test Capital-at-Risk Integrity
↓
Establish Governed Capital-at-Risk State
↓
Consolidate Governed Strategic Value State
↓
Handoff to Intelligence Sustainability Governance
168. Governance Outputs
CARM may produce:
Capital-at-Risk Object
Capital-at-Risk Boundary
Historical Capital State
Sunk Capital State
Recoverable Capital State
Committed Capital State
Current Capital Exposure
Incremental Capital-at-Risk
Cumulative Capital Exposure
Exposure Growth State
Exposure Duration State
Exposure Aging State
Capital Irreversibility State
Capital Flexibility State
Capital Lock-In State
Capital Concentration State
Dependency-Adjusted Exposure State
Remaining Capital Requirement
Capital Forecast State
Capital Overrun State
Capital Recovery State
Recovery-Adjusted Exposure State
Strategic Evidence State
Evidence Trend
Exposure Trend
Evidence-to-Exposure Relationship
Evidence-to-Capital Mismatch
Capital Gate State
Capital Exposure Limit State
Strategic Exposure Proportionality State
Capital-at-Risk Uncertainty State
Capital-at-Risk Confidence State
Capital-at-Risk Evidence Record
Capital-at-Risk Version
Capital-at-Risk Provenance
The principal module output is:
Governed Capital-at-Risk State
The consolidated Parent Standard output is:
Governed Strategic Value State
169. Critical Distinctions
CARM preserves the following distinctions:
Strategic Potential ≠ Unlimited Capital Justification
Capital-at-Risk ≠ Total Governed Cost
Capital-at-Risk ≠ Sunk Cost
Capital-at-Risk ≠ Realized Loss
Historical Expenditure ≠ Future Justification
Money Already Spent ≠ Reason to Spend More
Budget Availability ≠ Strategic Justification
Funding Availability ≠ Strategic Value
Capital Commitment ≠ Strategic Progress
Continued Spending ≠ Continued Strategic Progress
Large Investment ≠ Strong Strategic Thesis
Capital Lock-In ≠ Strategic Value
Milestone Achievement ≠ Investment Authority
Deferred Value ≠ Capital Authorization
Negative Immediate ROI ≠ Automatic Strategic Failure
Positive Immediate ROI ≠ Unlimited Strategic Capital Justification
Strategic Value ≠ Economic Exemption
Capital-at-Risk ≠ Liability
Investment ≠ Execution Authority
Capital-at-Risk State ≠ Final Investment Decision
170. Cross-Architecture Boundary
CARM governs Strategic Capital-at-Risk within SVGS.
SVIM governs Strategic Value Identification.
CVM governs Capability Value.
DVM governs Deferred Value.
SMM governs Strategic Milestones.
IES governs Intelligence Economy.
ISS governs long-term Intelligence Sustainability.
VAS governs detailed Value Attribution.
DGS governs lifecycle Decision Governance.
RGS governs Resource Governance.
VGS governs Value.
VALIDOS™ may govern validation methodology.
ADIT® may govern evidence and auditability.
HAGA™ governs Harm.
LIGA™ governs Liability.
CARM may consume governed evidence from these spaces without replacing their methodologies.
171. Canonical Boundary
CARM begins when economic commitment remains materially exposed to uncertainty because Strategic Value has not yet been fully realized.
CARM governs:
Capital-at-Risk Objects,
Capital-at-Risk Boundaries,
Historical Capital,
Sunk Capital,
Recoverable Capital,
Committed Capital,
Uncommitted Future Capital,
Current Capital Exposure,
Incremental Capital-at-Risk,
Cumulative Capital Exposure,
exposure growth,
exposure reduction,
Evidence-to-Exposure relationships,
Evidence Escalation,
Evidence Deficits,
Evidence-to-Capital mismatches,
Strategic Exposure Proportionality,
Capital-at-Risk horizons,
Exposure Duration,
Exposure Aging,
Capability Value relationships,
Deferred Value relationships,
Strategic Milestone relationships,
Capital Release Conditions,
Capital Gates,
Exposure Limits,
opportunity-cost visibility,
capital concentration,
dependency-adjusted exposure,
capital irreversibility,
reversible commitments,
staged commitment,
front-loaded exposure,
back-loaded exposure,
Capital Flexibility,
Capital Lock-In,
sunk-cost escalation,
commitment momentum,
Capital-at-Risk Baselines,
Exposure Increments,
Exposure Trends,
Evidence Trends,
Exposure-Evidence Trajectories,
Remaining Capital Requirements,
cost escalation,
Capital Overruns,
Capital Forecasts,
Capital Recovery,
asset reuse,
recovery-adjusted exposure,
uncertainty,
confidence,
drift,
reassessment,
versioning,
and provenance.
CARM does not independently govern:
general financial accounting,
general corporate capital allocation,
portfolio optimization,
banking capital,
financial-market risk,
Value definition,
Intelligence ROI methodology,
long-term Intelligence Sustainability,
final Value Attribution,
Harm,
Liability,
investment authority,
execution authority,
continuation,
scaling,
migration,
retirement,
or final lifecycle decisions.
CARM ends when strategic economic exposure has been represented as a:
Governed Capital-at-Risk State
and consolidated with the upstream SVGS states into a:
Governed Strategic Value State
for subsequent Intelligence Sustainability governance.
172. Use Case 1 — Frontier AI Research Requires Another Major Investment
An organization has invested heavily in a frontier intelligence research program.
The program has not yet generated positive immediate ROI.
However, it has produced:
a demonstrated new capability,
validated technical learning,
several achieved Strategic Milestones,
and a credible Deferred Value pathway.
Management proposes another major capital commitment.
CARM does not answer simply:
“ROI is negative, stop,”
or:
“Strategic Value exists, continue.”
Instead, it establishes:
current capital exposure,
sunk and recoverable capital,
additional proposed exposure,
evidence strength,
Capability Value,
Deferred Value credibility,
milestone progress,
remaining uncertainty,
critical dependencies,
and the relationship between increasing exposure and increasing strategic evidence.
The resulting Governed Capital-at-Risk State becomes evidence for subsequent governance.
Negative Immediate ROI ≠ Automatic Strategic Failure.
Strategic Value ≠ Unlimited Capital Justification.
173. Use Case 2 — Capital Keeps Increasing While Evidence Stays the Same
An AI initiative begins as a limited experiment.
The initial exposure is small and substantial uncertainty is acceptable.
Over several years:
investment increases significantly,
infrastructure commitments become difficult to reverse,
the Value horizon repeatedly moves further into the future,
critical milestones remain delayed,
and the evidence supporting the original Strategic Value thesis changes very little.
CARM identifies:
rising exposure,
increasing lock-in,
static evidence,
milestone weakness,
longer exposure duration,
and an Evidence-to-Capital Mismatch.
Past expenditure cannot repair that mismatch.
Money Already Spent ≠ Reason to Spend More.
Capital commitment should not grow faster than strategic justification.
174. Canonical Closing Statement
Strategic investment always contains uncertainty.
That is not the governance failure.
The failure begins when capital commitment can increase without the evidence supporting it becoming stronger.
Early exploration may operate with limited evidence because exposure is limited.
Large commitment cannot rely indefinitely on the same uncertainty that justified the first experiment.
Capital changes the burden of proof.
The more that becomes committed, irreversible, concentrated, or dependent on future Value, the more clearly the Strategic Value thesis must demonstrate why that exposure remains defensible.
Money Already Spent ≠ Reason to Spend More.
Continued Spending ≠ Continued Strategic Progress.
Strategic Potential ≠ Unlimited Capital Justification.
Capital commitment should not grow faster than strategic justification.
CARM governs the point where belief in future Value meets the economic consequence of being wrong.